Secondly, checking reported side effects (or the lack thereof) provides insight into safety and tolerance. ProstaVive is ...

CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) and Elevated Markers of Cardiac Stress Dr. Amish ...

Daxor’s Innovative ezBVA Lab Service Drives Accessibility and Operational Efficiency ...

Title: Long-term Safety and Efficacy Data with Inhaled Pirfenidone (AP01) in the ATLAS Open-label Extension Study Up to 240 Weeks Authors: Tamera J. Corte, Sebastien Tilleux, Deepthi K. Nair, Felix A.

Vaxil announces that it will be consolidating all of the issued and outstanding common shares of the Company (" Common Shares ") on the basis of one (1) post consolidation Common Share for each fifty ...

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through ...

PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the first quarter ending March 31, 2025 and provided a business ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders, ...

WALTHAM, Mass. and BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

The fireside chats will be webcasted and available under “Events & Presentations” in the Investor Relations section of the Company’s website at www.rhythmtx.com, and webcast replays will be available ...

DrEO Clinic has been recognized as the best hair transplant clinic in Mexico for 2025, reinforcing its position at the ...

Manufactured in GMP-compliant facilities, Arialief also earns trust by avoiding exaggerated claims, instead promoting gradual ...